- Home
- ECAT vs NNNN Comparison
ECAT vs NNNN Comparison
Compare ECAT & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ECAT | NNNN |
|---|---|---|
| Founded | 2021 | 2021 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.3B |
| IPO Year | N/A | 2025 |
Fundamental Metrics
Financial Performance| Metric | ECAT | NNNN |
|---|---|---|
| Price | $15.57 | $32.30 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 278.6K | 27.3K |
| Earning Date | 01-01-0001 | 04-28-2026 |
| Dividend Yield | ★ 9.20% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.39 | 0.06 |
| Revenue | N/A | ★ $8,185,146.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $7.15 | $518.11 |
| Revenue Growth | N/A | ★ 21.95 |
| 52 Week Low | $14.02 | $5.18 |
| 52 Week High | $17.30 | $55.65 |
Technical Indicators
Market Signals| Indicator | ECAT | NNNN |
|---|---|---|
| Relative Strength Index (RSI) | 39.86 | 56.49 |
| Support Level | $15.55 | $26.06 |
| Resistance Level | $15.85 | $44.73 |
| Average True Range (ATR) | 0.18 | 6.09 |
| MACD | -0.00 | -0.20 |
| Stochastic Oscillator | 0.93 | 50.51 |
Price Performance
Historical ComparisonAbout ECAT BlackRock ESG Capital Allocation Term Trust of Beneficial Interest
BlackRock ESG Capital Allocation Trust is a non-diversified, closed-ended management investment company. The Trust's investment objectives are to provide total return and income through a combination of current income, current gains, and long-term capital appreciation.
About NNNN Anbio Biotechnology Class A Ordinary Shares
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.